Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
ASPIRE
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough
1 other identifier
interventional
455
6 countries
107
Brief Summary
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Sep 2024
107 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 11, 2024
CompletedFirst Posted
Study publicly available on registry
July 16, 2024
CompletedStudy Start
First participant enrolled
September 24, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 10, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2026
CompletedFebruary 17, 2026
November 1, 2025
1.5 years
July 11, 2024
February 13, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in 24-hour Coughs per hour from Baseline
Change in 24-hour Coughs per hour from Baseline will be based on VitaloJAK® Cough Counts. The VitaloJAK® is a 510(k)-cleared medical device consisting of a digital sound recorder with 2 microphones; a lapel air microphone attached to the participant's clothing and an adhesive chest wall microphone which is attached to the skin at the top of the sternum.
Baseline to End of Treatment
Secondary Outcomes (6)
Change in Awake coughs per hour from Baseline
Baseline to End of Treatment
Change in the Cough Severity Visual Analog Scale from Baseline
Baseline to End of Treatment
Change in the Urge to Cough Visual Analog Scale from Baseline
Baseline to End of Treatment
Change in the Leicester Cough Questionnaire from Baseline
Baseline to End of Treatment
Patient Global Impressions of Improvement score
End of Treatment
- +1 more secondary outcomes
Study Arms (4)
NOC-110 1mg
EXPERIMENTALNOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler.
NOC-110 3mg
EXPERIMENTALNOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler.
NOC-110 6mg
EXPERIMENTALNOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler.
Placebo
PLACEBO COMPARATORThe matching placebo contains inhalation grade lactose blended with arginine. The blend is taste masked to the active drug product to minimize unblinding due to taste differences. The matching placebo will be administered via the same inhaler.
Interventions
Eligibility Criteria
You may qualify if:
- Refractory or unexplained chronic cough for ≥ 12 months.
- Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study.
- Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol.
- Able to provide Informed Consent.
You may not qualify if:
- Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds.
- Participants who are currently participating in another drug or device clinical study
- Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening.
- Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease.
- Respiratory tract infection within 4 weeks of Screening or during screening period.
- Any female who is pregnant or lactating or wishing to become pregnant.
- Donation of \> 1 Unit (450 milliliter or more) of blood within 60 days prior to the first dosing.
- Alcohol or drug use disorder within the past 2 years.
- Current smoker/vaper or individuals who have given up smoking within the past 6 months of screening, and/or those with \>20 pack-year smoking history.
- Current opiate/opioid use or medical history of opiate/opioid use disorder.
- History of concurrent malignancy or recurrence of malignancy in the last 2 years.
- Body Mass Index of ≥40 kg/m2.
- Positive results for human immunodeficiency virus, hepatitis B, or hepatitis C virus.
- Unable to refrain from the use of medications and treatments that can impact cough during the study.
- Have clinically significant history or evidence of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nocion Therapeuticslead
- Iqvia Pty Ltdcollaborator
Study Sites (107)
G & L Research, LLC
Foley, Alabama, 36535, United States
Medical Research of Arizona
Scottsdale, Arizona, 85251, United States
AMR Phoenix
Tempe, Arizona, 85281, United States
Little Rock Allergy & Asthma, P.A. Clinical Research Center
Little Rock, Arkansas, 72205, United States
So Cal Clinical Research
Huntington Beach, California, 92647, United States
Allergy and Asthma Associates of Southern California dba Southern California Research
Laguna Niguel, California, 92677, United States
Paradigm Clinical Research Centers, LLC - Modesto
Modesto, California, 95355, United States
NewportNativeMD,Inc
Newport Beach, California, 92663, United States
Center for Clinical Trials, LLC
Paramount, California, 90723, United States
Paradigm Clinical Research Centers, LLC
Redding, California, 96001, United States
DaVinci Research LLC.
Roseville, California, 95661, United States
Allergy & Asthma Associates of Santa Clara Valley
San Jose, California, 95117, United States
California Allergy & Asthma Medical Group Inc.
San Jose, California, 95117, United States
Allergy, Asthma, and Immunology Medical Group
Ventura, California, 93003, United States
Allergy and Asthma Clinical Research Inc
Walnut Creek, California, 94598, United States
Lynn Institute of Denver
Aurora, Colorado, 80012, United States
Innovative Research of West Florida, Inc.
Clearwater, Florida, 33756, United States
Omega Research Debary, LLC
DeBary, Florida, 32713, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
Clinical Site Partners, LLC Leesburg dba Flourish Research
Leesburg, Florida, 34748, United States
Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research
Miami, Florida, 33135, United States
Well Pharma Medical Research Corporation
Miami, Florida, 33173, United States
University of South Florida - PARENT
Tampa, Florida, 33613, United States
Clinical Site Partners, LLC Orlando dba Flourish Research
Winter Park, Florida, 32789, United States
Clinical Site Partners, LLC Orlando dba Flourish Research
Winter Park, Florida, 32789, United States
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah, Georgia, 31406, United States
Duly Health and Care
Winfield, Illinois, 60190, United States
Accellacare of McFarland Clinic
Ames, Iowa, 50010, United States
The Iowa Clinic, PC
West Des Moines, Iowa, 50266, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Bluegrass Allergy Research
Lexington, Kentucky, 40509, United States
Allergy & Asthma Specialists, PSC
Owensboro, Kentucky, 42301, United States
Continental Clinical Solutions, LLC
Towson, Maryland, 21204, United States
Infinity Medical Research Inc
Russells Mills, Massachusetts, 02747, United States
Clinical Research Institute
Minneapolis, Minnesota, 55402, United States
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
The Curators of the University of Missouri on behalf of University of Missouri Health Care
Columbia, Missouri, 65212, United States
Midwest Chest Consultants
Saint Charles, Missouri, 63301, United States
Sundance Clinical Research
St Louis, Missouri, 63141, United States
The Clinical Research Center, LLC
St Louis, Missouri, 63141, United States
Montana Medical Research, Inc.
Missoula, Montana, 59808, United States
AMR Las Vegas
Las Vegas, Nevada, 89119, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Allergy Partners of New Jersey P C
Ocean City, New Jersey, 07712, United States
The Valley Hospital
Paramus, New Jersey, 07652, United States
St Josephs Physicians Med PC Pulmonary Health
Liverpool, New York, 13088, United States
Equity Medical LLC
New York, New York, 10023, United States
Allergy Partners Clinical Research
Asheville, North Carolina, 28803, United States
Clinical Research of Gastonia
Gastonia, North Carolina, 28054, United States
M3 Wake Research, Inc.
Raleigh, North Carolina, 27612, United States
Accellacare
Winston-Salem, North Carolina, 27103, United States
Southeastern Research Center LLC
Winston-Salem, North Carolina, 27103, United States
Remington-Davis, Inc.
Columbus, Ohio, 43215, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73112, United States
Vital Prospects Clinical Research Institute, P.C.
Tulsa, Oklahoma, 74136, United States
Northwest Research Center
Portland, Oregon, 97202, United States
Suburban Research Associates
West Chester, Pennsylvania, 19380, United States
Care Access Research - Warwick 1
Warwick, Rhode Island, 02886, United States
Lowcountry Lung and Critical Care, P.A.
Charleston, South Carolina, 29406, United States
Accellacare
Mt. Pleasant, South Carolina, 29464, United States
Clinical Research of Rock Hill
Rock Hill, South Carolina, 29732, United States
Internal Medicine and Pediatric Associates of Bristol, PC
Bristol, Tennessee, 37620, United States
Accellacare d/b/a Accellacare of Knoxville
Knoxville, Tennessee, 37938, United States
Pharmaceutical Research & Consulting, Inc.
Dallas, Texas, 75231, United States
Houston Methodist Hospital
Houston, Texas, 77030, United States
South Texas Allergy & Asthma Medical Professionals
San Antonio, Texas, 78229, United States
Alamo ENT Associates
San Antonio, Texas, 78258, United States
TPMG Clinical Research Williamsburg
Williamsburg, Virginia, 23188, United States
Allergy, Asthma & Sinus Center, SC
Greenfield, Wisconsin, 53228, United States
UZ Leuven
Leuven, 3000, Belgium
AZ Sint-Maarten
Mechelen, 2800, Belgium
Pneumocare
Namur, 5380, Belgium
AZ Delta
Roeselare, 8800, Belgium
Dynamic Drug Advancement
Ajax, Ontario, L1S 2J5, Canada
BLC Clinical Research
Burlington, Ontario, L7N 3V2, Canada
McMaster University
Hamilton, Ontario, L8N 3Z5, Canada
Inspiration Research Limited
Toronto, Ontario, M5T 3A9, Canada
Recherche GCP Research
Montreal, Quebec, H1Y 3H5, Canada
DIEX Recherche Quebec Inc.
Québec, Quebec, G1V 4T3, Canada
Clinique Specialisee en Allergie de la Capitale
Québec, Quebec, G1V 4W2, Canada
Clinique de pneumologie et du sommeil de Lanaudière
Saint-Charles-Borromée, Quebec, J6E 2B4, Canada
DIEX Recherche Sherbrooke Inc.
Sherbrooke, Quebec, J1L 0H8, Canada
DIEX Recherche Victoriaville Inc.
Victoriaville, Quebec, G6P 3Z8, Canada
Pneumologisches Studienzentrum Muenchen West
Munich, Bavaria, 81241, Germany
Lungenzentrum Darmstadt
Darmstadt, Hesse, 64283, Germany
Medaimun GmbH
Frankfurt am Main, Hesse, 60596, Germany
Zentrum fuer ambulante pneumologische Forschung Marburg GbR
Marburg, Hesse, 35037, Germany
Pneumologicum Halle
Halle, Saxony-Anhalt, 06108, Germany
Pneumologisches Forschungsinstitut Hohegeest GbR
Geesthacht, Schleswig-Holstein, Germany
Velocity Research Germany GmbH
Lübeck, Schleswig-Holstein, 23552, Germany
Pneumologisches Studienzentrum MVZ "Die Lungenärzte"
Berlin, State of Berlin, 10961, Germany
Prywatny Gabinet Internistyczno-Alergologiczny
Bialystok, 15-010, Poland
Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny
Bialystok, 15-430, Poland
Centrum Medyczne Pratia Bydgoszcz
Bydgoszcz, 85-796, Poland
Centrum Medyczne Pratia Czestochowa
Częstochowa, 42-217, Poland
Ostrowieckie Centrum Medyczne spółka cywilna Anna Olech-Cudzik, Krzysztof Cudzik
Ostrowiec Świętokrzyski, 27-400, Poland
Centrum Medyczne Lucyna Andrzej Dymek s.c.
Strzelce Opolskie, 47-100, Poland
Gabinet Pulmonologii i Diagnostyki Chorób Alergicznych Dorota Maria Małosek
Szczecin, 70-1111, Poland
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. Z .O.O.
Tarnów, 33-100, Poland
Ormeau Clinical Trials Ltd
Belfast, Belfast, BT2 8BG, United Kingdom
Belfast City Hospital
Belfast, Belfast, BT9 7AB, United Kingdom
West Walk Surgery
Bristol, Bristol, BS374AX, United Kingdom
Castle Hill Hospital
Cottingham, East Riding of Yorkshire, HU16 5JQ, United Kingdom
King's College Hospital
London, Greater London, SE5 9RS, United Kingdom
Wythenshawe Hospital
Wythenshawe, Greater Manchester, M23 9LT, United Kingdom
Nottingham City Hospital
Nottingham, Nottinghamshire, NG56EG, United Kingdom
North Tyneside General Hospital
North Shields, Tyne & Wear, NE29 8NH, United Kingdom
Study Officials
- STUDY DIRECTOR
Matthew Frankel, MD
Chief Medical Officer Nocion Therapeutics, Inc.
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 11, 2024
First Posted
July 16, 2024
Study Start
September 24, 2024
Primary Completion
April 10, 2026
Study Completion
April 10, 2026
Last Updated
February 17, 2026
Record last verified: 2025-11